Incyte Announces the FDA Approved its Opzelura Cream for the Treatment of Vitiligo

Incyte Announces FDA Approval of Opzelura Cream for Vitiligo
Incyte (INCY) announced today, July 19, 2022, that the United States Food and Drug Administration (FDA) has approved Opzelura™ (ruxolitinib) cream 1.5% for the topical treatment of nonsegmental vitiligo in 12 years old patients and older.

Opzelura is the first and only FDA-approved treatment for . . .

This content is for paid subscribers.
Please click here to subscribe or here to log in.